{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:41:41Z","timestamp":1794631301657,"version":"4.9.1"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,2,28]],"date-time":"2012-02-28T00:00:00Z","timestamp":1330387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To conduct a long\u2010term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Fifty\u2010nine patients with CV and related skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy were enrolled. In CV patients who also had hepatitis C virus (HCV) infection, treatment of the HCV infection with antiviral agents had previously failed or was not indicated. Patients were randomized to the non\u2010RTX group (to receive conventional treatment, consisting of 1 of the following 3: glucocorticoids; azathioprine or cyclophosphamide; or plasmapheresis) or the RTX group (to receive 2 infusions of 1 gm each, with a lowering of the glucocorticoid dosage when possible, and with a second course of RTX at relapse). Patients in the non\u2010RTX group who did not respond to treatment could be switched to the RTX group. Study duration was 24 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Survival of treatment at 12 months (i.e., the proportion of patients who continued taking their initial therapy), the primary end point, was statistically higher in the RTX group (64.3% versus 3.5% [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001]), as well as at 3 months (92.9% versus 13.8% [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001]), 6 months (71.4% versus 3.5% [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001]), and 24 months (60.7% versus 3.5% [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001]). The Birmingham Vasculitis Activity Score decreased only after treatment with RTX (from a mean \u00b1 SD of 11.9 \u00b1 5.4 at baseline to 7.1 \u00b1 5.7 at month 2;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) up to month 24 (4.4 \u00b1 4.6;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001). RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy. The median duration of response to RTX was 18 months. Overall, RTX treatment was well tolerated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.34331","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T15:25:11Z","timestamp":1323185111000},"page":"843-853","source":"Crossref","is-referenced-by-count":358,"title":["A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis"],"prefix":"10.1002","volume":"64","author":[{"given":"S.","family":"De Vita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Quartuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Isola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mazzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Scaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Naclerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pietrogrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Mascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Masolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zabotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. L.","family":"Zignego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pioltelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Filippini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Perrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Migliaresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bombardieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,28]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(66)90199-9"},{"key":"e_1_2_7_3_2","first-page":"621","article-title":"Association between hepatitis C virus and mixed cryoglobulinemia","volume":"19","author":"Ferri C","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.2.569"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70129-5"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<94::AID-ANR12>3.0.CO;2-8"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/blood.V96.10.3578","article-title":"Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus\u2013associated non\u2010Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor\u2010producing cells that occur mainly in type II cryoglobulinemia","volume":"96","author":"De Re V","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115007"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.05.005"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404201"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20958"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.10.031"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel389"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23305"},{"issue":"13","key":"e_1_2_7_15_2","first-page":"S191","article-title":"Guidelines for the management of essential mixed cryoglobulinemia","volume":"13","author":"Tavoni A","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_16_2","first-page":"1157","article-title":"Rituximab for the treatment of type II mixed cryoglobulinemia","volume":"84","author":"Zaja F","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2856"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3162"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh469"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel004"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000183749.79424.b4"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.06.008"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24703"},{"key":"e_1_2_7_24_2","first-page":"iii234\u20105","article-title":"Effects of rituximab in a large series of patients with HCV\u2010associated mixed cryoglobulinemia syndrome","volume":"69","author":"Ferri C","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"e_1_2_7_25_2","first-page":"S123","article-title":"Classification of the cryoglobulinemic syndrome","volume":"13","author":"Invernizzi F","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.01.008"},{"key":"e_1_2_7_28_2","first-page":"319","article-title":"Birmingham Vasculitis Activity Score, Disease Extent Index and complement factor C3c reflect disease activity best in hepatitis C virus\u2010associated cryoglobulinemic vasculitis","volume":"18","author":"Lamprecht P","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150755"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20318"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1004992"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.78"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.10.001"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126573"},{"key":"e_1_2_7_35_2","first-page":"84","article-title":"Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia","volume":"28","author":"Quartuccio L","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-122713"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084939"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106174"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh470"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-245878"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.25000"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248518"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253948"},{"key":"e_1_2_7_46_2","first-page":"S99","article-title":"Treatment of mixed cryoglobulinemia: a rheumatology perspective","volume":"29","author":"De Vita S","year":"2011","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.34331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.34331","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.34331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:22:43Z","timestamp":1696965763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.34331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,28]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1002\/art.34331"],"URL":"https:\/\/doi.org\/10.1002\/art.34331","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,28]]}}}